 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Paul Lee] According to pharmaceutical industry sources, Hanmi Science, the holding company of the Hanmi Pharmaceutical Group, has transitioned from a joint CEO system with Chairman Song Young-sook and her son, President Lim Jong-hoon, to a sole CEO system under President Lim Jong-hoon. Despite initially advocating for family unity following recent conflicts over control within the family, Hanmi Group ultimately shifted to a sole CEO structure after just over a month.
On the 16th, it was reported that during an interim board meeting held at 10 a.m. on the 14th, the proposal to transition from the current joint CEO system to a sole CEO system under Lim Jong-hoon was approved. The company is expected to disclose the decisions made during the board meeting, including the change in the CEO structure.
Following the interim board's decision, it is anticipated that Chairman Song will step down from her position as joint CEO of Hanmi Science. This decision comes just 40 days after the establishment of the joint CEO system between Lim Jong-hoon and the incumbent Chairman Song Young-sook during a board meeting on April 4th, where the family expressed their willingness to reconcile. The change in leadership structure is reported to be primarily driven by disagreements among family members, particularly between siblings and between parents and children.
During the first board meeting held after the governance dispute, the family agreed to lead the new Hanmi based on family cooperation.
Alphabiz Reporter Kim SangJin(hoondork1977@alphabiz.co.kr)
